Michel Attal
University Hosptial toulouse · University Hospital, Toulouse · University Hospital of Toulouse
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michel Attal as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:19 UTC. Open this list on ClinicalTrials.gov
- N/ANCT03679351 · "FU-IFM2009" Database Post IFM/DFCI 2009 StudyUniversity Hospital, Toulouse · unknown · Multiple Myeloma · principal investigator
- Ph2NCT03669445 · Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple MyelomaUniversity Hospital, Toulouse · unknown · Multiple Myeloma · study director
- Ph2NCT02897830 · Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple MyelomaUniversity Hospital, Toulouse · terminated · Multiple Myeloma · principal investigator
- Ph2NCT02405364 · Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone InductionUniversity Hospital, Toulouse · completed · Multiple Myeloma · principal investigator
- Ph3NCT02197221 · Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple MyelomaUniversity Hospital, Toulouse · completed · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT01279694 · Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)Nantes University Hospital · completed · Myeloma · principal investigator
- Ph2NCT01206205 · Frontline Therapy in de Novo Multiple Myeloma Patients Under 65University Hospital, Toulouse · completed · Multiple Myeloma · principal investigator
- Ph3NCT01191060 · Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 YearsUniversity Hospital, Toulouse · completed · Myeloma · principal investigator
- Ph2NCT01053949 · IFM2009-02-Pomalidomide and Dexamethasone Phase 2 MyelomaUniversity Hospital, Lille · completed · Multiple Myeloma · principal investigator
- Ph2NCT00999830 · Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple MyelomaInnate Pharma · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:19 UTC. The ranking covers the 200 most relevant of 97 PubMed records, and a shared surname and initials can bring in a namesake. All 97 on PubMed
- A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.N Engl J Med · 19962,382 citationsRCR 60.7
- Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.N Engl J Med · 20071,205 citationsRCR 26.6
- 1,045 citationsRCR 36.3
- 960 citationsRCR 25.8
- 854 citationsRCR 35.4
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.N Engl J Med · 2019853 citationsRCR 33.9
- 811 citationsRCR 17.6
- 726 citationsRCR 15.4
- 671 citationsRCR 15.8
- 666 citationsRCR 19.7